p.119 抽出テキスト

lialization. Circulation 2007; 115: 2435-2441. PMID: 17438147 444. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705. PMID: 14744976 445. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419. PMID: 16432073 446. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-1322. PMID: 21376502 447. Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 2009; 54: 1924-1931. PMID: 19909872 448. Imai M, Kadota K, Goto T, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation 2011; 123: 2382-2391. PMID: 21576652 449. Tada T, Kadota K, Hosogi S, et al. Optical coherence tomography findings in lesions after sirolimus-eluting stent implantation with peristent contrast staining. Circ Cardiovasc Interv 2012; 5: 649-656. PMID: 23011265 450. Radu MD, Räber L, Kalesan B, et al. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. Eur Heart J 2014; 35: 795-807. PMID: 24132187 451. Yamaji K, Räber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J 2016; 37: 3386-3395. PMID: 27578808 452. Alfonso F, Dutary J, Paulo M, et al. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. Heart 2012; 98: 1213-1220. PMID: 22826559 453. Miura K, Kadota K, Habara S, et al. Ten-year clinical outcomes after sirolimus-eluting stent implantation: Impact of an in-stent restenosis target lesion. Am Heart J 2016; 175: 47-55. PMID: 27179723 454. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722. PMID: 24004642 455. Fuku Y, Kadota K, Amano H, et al. Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation. Circ J 2017; 82: 211-217. PMID: 28855451 456. Kubo S, Kadota K, Ichinohe T, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis. Circ J 2014; 78: 101-109. PMID: 24189504 457. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012; 5: 131-140. PMID: 22361596 458. Masuda M, Okumura M, Doki Y, et al. Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2014 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2016; 64: 665-697. PMID: 27590348 459. Ghanta RK, Kaneko T, Gammie JS, et al. Evolving trends of reoperative coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. J Thorac Cardiovasc Surg 2013; 145: 364-372. PMID: 23321128 460. Yap CH, Sposato L, Akowuah E, et al. Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. Ann Thorac Surg 2009; 87: 1386-1391. PMID: 19379870 461. Dohi M, Miyata H, Doi K, et al. Japan Cardiovascular Surgery Database. The off-pump technique in redo coronary artery bypass grafting reduces mortality and major morbidities: propensity score analysis of data from the Japan Cardiovascular Surgery Database. Eur J Cardiothorac Surg 2015; 47: 299-308. PMID: 24623172 462. Bruno VD, Zakkar M, Rapetto F, et al. Early health outcome and 10year survival in patients undergoing redo coronary surgery with or without cardiopulmonary bypass: a propensity score-matched analysis. Eur J Cardiothorac Surg 2017; 52: 945-951. PMID: 28505298 463. Morrison DA, Sethi G, Sacks J, et al. Investigators of the Department of Veterans Affairs Cooperative Study #385, Angina With Extremely Serious Operative Mortality Evaluation. Percutaneous coronary inter- vention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002; 40: 1951-1954. PMID: 12475454 464. Subramanian S, Sabik JF, Houghtaling PL, et al. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. Ann Thorac Surg 2009; 87: 1392-1400. PMID: 19379872 465. Sabik JF, Raza S, Blackstone EH, et al. Value of internal thoracic artery grafting to the left anterior descending coronary artery at coronary reoperation. J Am Coll Cardiol 2013; 61: 302-310. PMID: 23328610 466. Dohi M, Doi K, Okawa K, et al. Upgrading redo coronary artery bypass graft by recycling in situ arterial graft. Ann Thorac Surg 2014; 98: 311-314. PMID: 24996709 467. Lip GY, Huber K, Andreotti F, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28. PMID: 20062939 468. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. PMID: 11401607 469. Goto K, Nakai K, Shizuta S, et al. CREDO-Kyoto Registry Cohort-2 Investigators. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 2014; 114: 70-78. PMID: 24925801 470. Kinjo K, Sato H, Sato H, et al. Osaka Acute Coronary Insufficiency Study (OACIS) Group. Prognostic significance of atrial fibrillation/ atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2003; 92: 1150- 1154. PMID: 14609587 471. Kosmidou I, Chen S, Kappetein AP, et al. New-onset atrial fibrillation after PCI or CABG for left main disease: The EXCEL Trial. J Am Coll Cardiol 2018; 71: 739-748. PMID: 29447735 472. Reddy VY, Doshi SK, Sievert H, et al. PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127: 720- 729. PMID: 23325525 473. Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 312: 1988-1998. PMID: 25399274 474. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64: 1-12. PMID: 24998121 475. Reddy VY, Doshi SK, Kar S, et al. PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964-2975. PMID: 29103847 476. Malaisrie SC, McCarthy PM, Kruse J, et al. Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2018; 155: 2358-2367.e1. PMID: 29523404 477. Saxena A, Virk SA, Bowman S, et al. Preoperative atrial fibrillation portends poor outcomes after coronary bypass graft surgery: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2018; 155: 1524-1533.e2. PMID: 29554786 478. Gillinov AM, Gelijns AC, Parides MK, et al. CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; 372: 1399-1409. PMID: 25853744 479. Al-Atassi T, Kimmaliardjuk DM, Dagenais C, et al. Should we ablate atrial fibrillation during coronary artery bypass grafting and aortic valve replacement? Ann Thorac Surg 2017; 104: 515-522. PMID: 28262298 480. Ad N, Henry L, Hunt S, et al. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypass surgery? J Thorac Cardiovasc Surg 2012; 143: 936-944. PMID: 22244503 481. Rankin JS, Lerner DJ, Braid-Forbes MJ, et al. One-year mortality and costs associated with surgical ablation for atrial fibrillation concomitant to coronary artery bypass grafting. Eur J Cardiothorac Surg 2017; 52: 471-477. PMID: 28472412 482. Damiano RJ, Gaynor SL, Bailey M, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg 2003; 126: 2016- 2021. PMID: 14688721